Vedanta Biosciences secures $60 million to complete Phase 3 trial of C. difficile microbiome therapy

Vedanta Biosciences, a Cambridge, MA biotech focused on microbiome therapeutics, announced it has raised $60 million in new financing.

The capital will be used to advance its lead candidate targeting recurrent Clostridioides difficile infection into a Phase 3 clinical trial, with readout expected next year.

The funding round reflects continued investor interest in microbiome approaches despite a challenging landscape, and positions Vedanta to potentially bring its therapy to market if trial results are positive.